Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

CANbridge Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Details:

Endogenous human SMN1 promoter-driven gene replacement improves the efficacy and safety of AAV9-mediated gene therapy for spinal muscular atrophy in mice.

Lead Product(s): AAV9-based Gene Therapy

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: UMass Chan Medical School

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 17, 2022

ASK
US

Upload
your Pipeline Activity

CANbridge Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Details:

Researchers will present findings from an endogenous human SMN1 promoter-driven gene replacement improves the efficacy and safety of aav9-mediated gene therapy for spinal muscular atrophy in mice.

Lead Product(s): AAV9-Based Gene Therapy

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: UMass Chan Medical School

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2022

ASK
US

Upload
your Pipeline Activity

EdiGene

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

EdiGene Raises Approximately USD 67 Million in Series B Financing to Advance Gene Editing Based Programs into Clinical Stage

Details:

EdiGene has established four gene editing based platforms and is advancing its early stage programs into clinical development for patients with genetic diseases and cancer. Proceeds from the financing will be used to advance the company’s pipeline into clinics.

Lead Product(s): ET-01

Therapeutic Area: Genetic Disease Product Name: ET-01

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: 3H Health Investment

Deal Size: $67.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing October 13, 2020

ASK
US

Upload
your Pipeline Activity

CANbridge Pharmaceuticals

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

CANbridge Pharmaceuticals Enters into Rare Disease Gene Therapy Research Agreement with UMass Medical School

Details:

This collaboration with the Horae Gene Therapy Center at UMass, affords CANbridge the potential to extend the rare disease pipeline by integrating next-generation technology to advance as a leader in the treatment of rare diseases by adeno-associated virus.

Lead Product(s): AAV9-mediated Gene Therapy

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: UMass Chan Medical School

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 09, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY